Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 104.11 Million SEK | 40.19% |
| 2022 | 74.27 Million SEK | 33.29% |
| 2021 | 55.72 Million SEK | 29.31% |
| 2020 | 43.09 Million SEK | 61.12% |
| 2019 | 26.74 Million SEK | 19.14% |
| 2018 | 22.44 Million SEK | 47.95% |
| 2017 | 15.17 Million SEK | -14.81% |
| 2016 | 17.81 Million SEK | 45.22% |
| 2015 | 12.26 Million SEK | -17.3% |
| 2014 | 14.83 Million SEK | -21.94% |
| 2013 | 18.99 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 18.45 Million SEK | -29.17% |
| 2023 Q2 | 27.55 Million SEK | 35.12% |
| 2023 FY | 104.11 Million SEK | 40.19% |
| 2023 Q1 | 20.39 Million SEK | 12.49% |
| 2023 Q4 | 26.05 Million SEK | -13.45% |
| 2023 Q3 | 30.1 Million SEK | 9.25% |
| 2022 Q2 | 20.22 Million SEK | 17.35% |
| 2022 Q1 | 17.23 Million SEK | -5.94% |
| 2022 FY | 74.27 Million SEK | 33.29% |
| 2022 Q4 | 18.13 Million SEK | -2.94% |
| 2022 Q3 | 18.68 Million SEK | -7.64% |
| 2021 Q2 | 11.88 Million SEK | -7.75% |
| 2021 Q1 | 12.88 Million SEK | 3.65% |
| 2021 FY | 55.72 Million SEK | 29.31% |
| 2021 Q4 | 18.32 Million SEK | 45.0% |
| 2021 Q3 | 12.63 Million SEK | 6.34% |
| 2020 Q3 | 10.87 Million SEK | -13.48% |
| 2020 FY | 43.09 Million SEK | 61.12% |
| 2020 Q4 | 12.42 Million SEK | 14.26% |
| 2020 Q2 | 12.57 Million SEK | 74.28% |
| 2020 Q1 | 7.21 Million SEK | 3.31% |
| 2019 Q4 | 6.98 Million SEK | -9.74% |
| 2019 FY | 26.74 Million SEK | 19.14% |
| 2019 Q1 | 3.96 Million SEK | -11.61% |
| 2019 Q2 | 8.05 Million SEK | 103.19% |
| 2019 Q3 | 7.73 Million SEK | -4.01% |
| 2018 FY | 22.44 Million SEK | 47.95% |
| 2018 Q4 | 4.48 Million SEK | -15.25% |
| 2018 Q3 | 5.29 Million SEK | -39.45% |
| 2018 Q2 | 8.74 Million SEK | 123.11% |
| 2018 Q1 | 3.92 Million SEK | 30.26% |
| 2017 Q1 | 5.76 Million SEK | 63.96% |
| 2017 FY | 15.17 Million SEK | -14.81% |
| 2017 Q4 | 3 Million SEK | 127.02% |
| 2017 Q3 | 1.32 Million SEK | -73.86% |
| 2017 Q2 | 5.07 Million SEK | -12.05% |
| 2016 Q3 | 4.65 Million SEK | 106.12% |
| 2016 Q1 | 7.38 Million SEK | 159.23% |
| 2016 FY | 17.81 Million SEK | 45.22% |
| 2016 Q2 | 2.25 Million SEK | -69.44% |
| 2016 Q4 | 3.51 Million SEK | -24.38% |
| 2015 Q4 | 2.84 Million SEK | -22.78% |
| 2015 Q3 | 3.68 Million SEK | 0.0% |
| 2015 FY | 12.26 Million SEK | -17.3% |
| 2014 FY | 14.83 Million SEK | -21.94% |
| 2013 FY | 18.99 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -1568.3% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 92.417% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 92.417% |
| Arcoma AB | 163.01 Million SEK | 36.129% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 48.959% |
| BICO Group AB (publ) | 2.23 Billion SEK | 95.351% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 81.776% |
| CellaVision AB (publ) | 677.29 Million SEK | 84.627% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -1158.535% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -10564.822% |
| C-Rad AB (publ) | 424.61 Million SEK | 75.479% |
| Duearity AB (publ) | 1.65 Million SEK | -6194.96% |
| Dignitana AB (publ) | 86.06 Million SEK | -20.98% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -910.861% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.673% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -1370.958% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -12081.906% |
| Mentice AB (publ) | 273.61 Million SEK | 61.946% |
| OssDsign AB (publ) | 112.15 Million SEK | 7.167% |
| Paxman AB (publ) | 210.11 Million SEK | 50.447% |
| Promimic AB (publ) | 37.07 Million SEK | -180.87% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -42571.571% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -347.918% |
| ScandiDos AB (publ) | 60.42 Million SEK | -72.299% |
| Sectra AB (publ) | 2.96 Billion SEK | 96.487% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 32.332% |
| Senzime AB (publ) | 35.75 Million SEK | -191.208% |
| SpectraCure AB (publ) | 318 Thousand SEK | -32641.708% |
| Stille AB | 294.89 Million SEK | 64.693% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 97.035% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 82.576% |